Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7818372

Failure of test yolk buffer to decrease antisperm antibodies on sperm.

D Katsoff·J H Check·J Kozak
View original source ↗Export metadata ↓

Abstract

The objective of this study was to evaluate whether the suspension of sperm naturally bound or artificially coated with antisperm antibody (ASA) in test yolk buffer (TYB) will reduce the percentage of sperm positive for ASA. Attempts were made to repeat a study performed by Lam et al., in which they claimed a significant decrease in percentage of sperm positive for both IgA and IgG. Furthermore, the study attempted to determine if this methodology would similarly reduce the percentage of sperm naturally bound with ASA. There was no reduction in postincubation levels in percentage of sperm having attachment of IgA or IgG in either the sperm specimens naturally bound with ASA or donor sperm artificially coated with antibodies. Incubation in TYB does not appear to be an effective method to reduce the percentage of sperm bound with ASA. Possibly, it could reduce the amount of ASA bound to each sperm, but this would have to be proven by other studies.

Explore related subjects

AntibodiesCells, CulturedGlucoseHumansImmunoglobulin AImmunoglobulin GInfertility, MaleMaleSpermatozoaTromethamineJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Katsoff, J H Check, J Kozak. Failure of test yolk buffer to decrease antisperm antibodies on sperm.. https://doi.org/10.3109/01485019408987815

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗
PubMed1996

Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cells.

The adhesion of cancer cells to vascular endothelium is an important step in the hematogenous metastasis of cancer. The authors investigated the alteration of integrin expression in human esophageal cancer cells, following the selectin-mediated initial adhesion to endothelial cells. The expression of alpha2 beta1 and alpha3 beta1 integrins in esophageal cancer cells (TE-1 and T.Tn), strongly expressing EGF-receptors, were markedly increased by the addition of the heparin-binding EGF like growth factor (HB-EGF). The increase of integrin expression in esophageal cancer cells was inhibited by the addition of the tyrosine kinase inhibitor, genistein. HB-EGF treatment of esophageal cancer cells resulted in the augmentation of cancer cell adhesion to immobilized collagen. When esophageal cancer cells were co-cultured with endothelial cells, similar levels of augmentation of cancer cell adhesion to collagen were observed. The augmentation of cancer cell adhesion to collagen was inhibited by the addition of anti-HB-EGF neutralizing antibody. Our interpretation of the results described above is that the cancer cells receive stimulation from cytokines, such as HB-EGF, produced by endothelial cells, following initial adhesion of cancer cells via selectins. This results in a secondary increase in the expression of cell adhesion molecules, such as the beta1 integrin family, and leads to augmentation in the adhesive activities of cancer cells at vessel walls. We postulate that this sequence of events involves the enhanced transmigration of cancer cells to extravascular tissues, following the selectin-mediated adhesion to the endothelium.

Antibodies↗
PubMed1996

The effect of type III collagen on migration and invasion of human glioblastoma cell lines in vitro.

The effect of type III collagen, an extracellular matrix protein, on the in vitro migration and invasion of glioblastoma cells was assayed by chemotaxis using four cell lines. Migration and invasion of gliomablastoma cells was observed in the presence of varying concentrations of type III collagen. In contrast to control experiments in which the protein was not added, type III collagen significantly increased migration and invasion of glioblastoma cells in a dose dependent manner up to 10 micrograms/ml; however, higher concentrations of the protein eliminated this affect on migration and invasion as did the presence of a monoclonal type III collagen antibody. Type III collagen was also shown to stimulate the migration of glioblastoma cells from spheroids to monolayers. The results of this study indicate that type III collagen does influence the migration and invasion of human glioblastoma cells in vitro.

Antibodies↗